Company & Sponsor Intelligence

Emory University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials17

Recruiting2

Completed10

Countries1

Therapeutic footprint

alzheimersanxietyautismdepressionepilepsyparkinsonsptsd

Indexed studies

NCT03311711Preparation for End-of-Life Decision Making in Mild Dementia
alzheimers · United StatesNA

NCT02300584Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program
alzheimers · United StatesNA

NCT04710004Electrophysiological Biomarkers in MTLE Patients.
epilepsy · United StatesNA

NCT01522404Effects of Atomoxetine in Mild Cognitive Impairment
alzheimers · United StatesPHASE2

NCT04325204Faith-Based Toolbox for African Americans With Dementia
alzheimers · United StatesNA

NCT02383732A Study of the Elopement Prevention and Safety Training Program
autism · United StatesNA

NCT06496425Inspiring Seniors Towards Exercise Promotion to Protect Cognition
alzheimers · United StatesNA

NCT07332143Psilocybin-Assisted Therapy
ptsd · United StatesPHASE2

NCT02464527Stimulus-Stimulus Pairing Study
autism · United StatesNA

NCT01740726Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression
depression · United StatesNA

NCT00726076Managing Epilepsy Well- WebEase Project
epilepsy · United StatesNA

NCT00208611Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease
parkinsons · United StatesPHASE2, PHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →